Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Non Operating Income (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Non Operating Income for 7 consecutive years, with -$477000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 100.84% year-over-year to -$477000.0, compared with a TTM value of -$1.9 million through Dec 2025, down 103.43%, and an annual FY2025 reading of -$1.9 million, down 103.43% over the prior year.
  • Non Operating Income was -$477000.0 for Q4 2025 at Avidity Biosciences, down from -$380000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $57.1 million in Q4 2024 and bottomed at -$17.7 million in Q4 2023.
  • Average Non Operating Income over 5 years is $2.7 million, with a median of -$73500.0 recorded in 2021.
  • Peak annual rise in Non Operating Income hit 12190.91% in 2022, while the deepest fall reached 12500.0% in 2022.
  • Year by year, Non Operating Income stood at -$46000.0 in 2021, then tumbled by 4728.26% to -$2.2 million in 2022, then plummeted by 695.68% to -$17.7 million in 2023, then surged by 423.01% to $57.1 million in 2024, then crashed by 100.84% to -$477000.0 in 2025.
  • Business Quant data shows Non Operating Income for RNA at -$477000.0 in Q4 2025, -$380000.0 in Q3 2025, and -$651000.0 in Q2 2025.